key: cord-0961763-c6x86zwh
authors: Whyte, Martin B.; Barker, Rosemary; Kelly, Philip A.; Gonzalez, Elisa; Czuprynska, Julia; Patel, Raj K.; Rea, Catherine; Perrin, Felicity; Waller, Michael; Jolley, Caroline; Arya, Roopen; Roberts, Lara N.
title: Three-month follow-up of Pulmonary Embolism in patients with COVID-19
date: 2021-02-26
journal: Thromb Res
DOI: 10.1016/j.thromres.2021.02.023
sha: 0221b0fe24d7303399a08af59fafdc6f7cb569db
doc_id: 961763
cord_uid: c6x86zwh

nan

Coronavirus disease 2019 (COVID-19) infection has been notable for the occurrence of pulmonary venous thrombosis, also known as immunothrombosis, in addition to classical pulmonary embolism. 1 The pathophysiology underpinning this appears more platelet-dependent and related to viralmediated endothelial inflammation, in addition to hypercoagulability. 2 To date, treatment of confirmed pulmonary embolism (PE) has followed established (pre-COVID) venous thromboembolism (VTE) guidelines 3 but it is not known whether the subsequent clinical behaviour of COVID-associated VTE differs from outcomes reported prior to the COVID-19 pandemic.

We have previously reported the rate, clinical characteristics and initial treatment of pulmonary embolus (PE) in a cohort of patients with clinically suspected or confirmed COVID-19 at King's College Hospital. 4 Given that the pathophysiology of immunothrombosis differs to classical pulmonary embolism, the clinical outcomes in these patients may also differ vis a vis risks of bleeding or recurrent thrombosis. The primary aim was to describe longer term clinical outcomes from n=77 patients with confirmed COVID and with at least 90 days of follow-up, or earlier death. As patients with severe COVID-19 had further imaging as part of a structured follow up protocol, 6 we also report rates of residual thrombosis in this subgroup.

Our approach to anticoagulation for VTE treatment in this cohort was to initiate anticoagulation with therapeutic enoxaparin (or an unfractionated heparin infusion for patients requiring renal replacement therapy with an APTR target of 2 -2.5). Patients were then reviewed by the anticoagulation team for the longer-term plan; usually to switch to an oral anticoagulant with recovery, nearer the time of discharge. Outcome data were collected from the Electronic Patient Record (EPR; Allscripts Sunrise™, Chicago, Il) including details of bleeding, recurrent thrombotic events, further imaging performed, choice and duration of anticoagulation. Bleeding complications were defined as per the ISTH definition for major bleeding (MB) encompassing fatal bleeding, symptomatic bleeding in a critical area or organ (intracranial, intraspinal, intraocular, retroperitoneal, intra-articular, pericardial, or intramuscular bleeding with compartment syndrome) and/or bleeding causing a fall in haemoglobin level of ≥ 2g/dl or leading to transfusion of ≥ 2 units of packed red cells or clinically relevant non-major bleeding (CRNMB; bleeding not meeting previous criteria but requiring intervention or escalation of care). 5 This data was extracted/confirmed by two authors (RB and LR). All patients surviving to hospital discharge were discharged with a three-month Major bleeds occurred seven times in n=6 (7.8%) patients. These were n=3 upper gastro-intestinal (GI); n=2 at bronchoscopy (one fatal); n=1 lower GI; and n=1 chest wall. CRNMB occurred six times in n=6 (7.8%) patients; a total therefore of n=8 (10%) patients experiencing bleeding events. Further details are provided in Table 2 . These were confined to patients requiring ICU care: all major bleeds occurred within the ICU during the index hospitalisation. All CRNM bleeds also occurred during index hospitalisation, with only one occurring after ICU discharge. Median time to first bleeding event was 31 days (range 1 -62 days) from PE diagnosis.

At hospital discharge, most patients (79%) were treated with direct oral anticoagulants (DOAC) as shown in Table 1 We report the thrombotic and bleeding outcomes at >90-days in patients with confirmed PE and COVID-19. In our cohort, the case fatality rate (in hospital death) was 25% -significantly higher than J o u r n a l P r e -p r o o f Journal Pre-proof the 9% reported in a large US series of PE just before the COVID-19 pandemic, 7 but broadly comparable with UK in-hospital mortality from COVID-19 of ~30%, over a similar phase of the epidemic. 8 Furthermore, the rate of major bleeding was comparable (9%) to pooled incidence rates reported in meta-analyses of bleeding in hospitalised patients with COVID-19, and lower than that reported in those receiving intermediate/therapeutic anticoagulation (21.4%). 1 Of note, no major bleeding events occurred after ICU or hospital discharge. Increased haemorrhage could reasonably be considered a result of endothelitis in the acute, severe manifestation of COVID-19 in the ICU. [2] Increased renal failure in ICU will also affect bleeding risk. The use of unfractionated heparin infusion with APTR monitoring may also have contributed to the bleeding rates given reports of underestimating anticoagulant activity in those with increased fibrinogen/Factor VIII. 9 We did not routinely perform anti-Factor Xa monitoring throughout this period, although four patients with bleeding events on UFH infusions had anti-Factor Xa measured, with results within acceptable limits (data not shown). Whether LMWH would be safer in the critically ill in view of its lesser bleeding risk remains uncertain, particularly in view of potential for accumulation in those with renal impairment.

The low rate for recurrent VTE (1.7%) that we found was similar to that reported following 6 month follow-up (3.9%) of unselected PE (n=439) 10 The high prevalence (30%) of residual thrombus was unexpected in those undergoing repeat imaging. Two prior studies investigated residual thrombosis in unselected PE populations; the ELOPE study reported residual thrombus in 12.2% at 12 months with no relationship to functional impairment. 11 The PROMETHEUS study reported residual thrombus in 15.9% of patients at 6 months. 12 Given the earlier timing of imaging in our study (to facilitate early detection of interstitial lung disease), it's possible residual thrombus further resolved at a later timepoint. However, as these patients did not have evidence of pulmonary hypertension, further serial imaging is not planned particularly as the clinical significance of residual thrombus remains uncertain. As in ELOPE, no patient developed CTEPH but this is perhaps unsurprising given the small cohort and short follow-up duration. 11 Following survival to ICU discharge, clinically important outcomes of bleeding and recurrent thrombosis are uncommon and comparable to those reported prior to COVID-19. Therefore, standard anticoagulation strategies appear appropriate. Major bleed, n (%) 7 (21) 0 7 (9) Clinically relevant non-major bleed, n (%) 6 Follow-up CTPA outcome Clot resolution 7 6 12 Reduction in clot burden 1 1 2 Clot persistence (unchanged) 5 1 6

Follow-up echocardiogram, n (%) 6 

Incidence of VTE and Bleeding Among Hospitalized Patients With Coronavirus Disease 2019: A Systematic Review and Meta-analysis

Diagnosis, Management, and Pathophysiology of Arterial and Venous Thrombosis in COVID-19

Scientific and Standardization Committee communication: Clinical guidance on the diagnosis, prevention, and treatment of venous thromboembolism in hospitalized patients with COVID-19

Pulmonary embolism in hospitalised patients with COVID-19

Subcommittee on Control of Anticoagulation of the S, Standardization Committee of the International Society on T, Haemostasis. Definition of major bleeding in clinical investigations of antihemostatic medicinal products in non-surgical patients

British Thoracic Society Guidance on Respiratory Follow Up of Patients with a Clinico-Radiological Diagnosis of COVID-19 Pneumonia

Identification, diagnosis, treatment, and in-hospital outcomes of acute pulmonary embolism: Results from a single integrated health system

Risk stratification of patients admitted to hospital with covid-19 using the ISARIC WHO Clinical Characterisation Protocol: development and validation of the 4C Mortality Score

Should we abandon the APTT for monitoring unfractionated heparin?

Outpatient or inpatient treatment for acute pulmonary embolism: a retrospective cohort study of 439 consecutive patients

Serial imaging after pulmonary embolism and correlation with functional limitation at 12 months: Results of the ELOPE Study

Thromboembolic resolution assessed by CT pulmonary angiography after treatment for acute pulmonary embolism

Martin B. Whyte, 1,2 Rosemary Barker, 1 Philip A. Kelly, 1 Elisa Gonzalez, 1 Julia Czuprynska, 3